| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Correspondence: Kelly K. Hunt, M.D., Chief, Surgical Breast Section, Department of Surgical Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, Texas 77030, USA. Telephone: 713-792-7216; Fax: 713-792-4689; e-mail: khunt{at}mdanderson.org
As of May 2001, 532 gene therapy protocols had been approved for evaluation in clinical trials; however, only five of those had been evaluated in phase III clinical trials. Among the most commonly used vectors for the delivery of genetic material into human cells are the adenoviruses. Remarkable progress has been made with these vectors in the last decade, but some shortcomings continue to challenge investigators. The newly acquired knowledge of the adenoviral life cycle and the positive outcomes from phase II clinical trials have led to the application of vectors engineered to selectively target tumor tissue under controlled promoters.
This article has been cited by other articles:
 |
|
 |
|
  Y. Omidi and J. Barar Induction of Human Alveolar Epithelial Cell Growth Factor Receptors by Dendrimeric Nanostructures International Journal of Toxicology, March 1, 2009; 28(2): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.H. Hassan, N. Khatoon, D.T. Curiel, F.M. Hamada, H.M. Arafa, and A. Al-Hendy Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells Hum. Reprod., March 1, 2008; 23(3): 514 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A R Lyon, M Sato, R J Hajjar, R J Samulski, and S E Harding Gene therapy: targeting the myocardium Heart, January 1, 2008; 94(1): 89 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. A. M. van Waardenburg, L. A. de Jong, M. A. J. van Eijndhoven, C. Verseyden, D. Pluim, L. E. T. Jansen, M.-A. Bjornsti, and J. H. M. Schellens Platinated DNA Adducts Enhance Poisoning of DNA Topoisomerase I by Camptothecin J. Biol. Chem., December 24, 2004; 279(52): 54502 - 54509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spankuch, Y. Matthess, R. Knecht, B. Zimmer, M. Kaufmann, and K. Strebhardt Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter-Driven Short Hairpin RNAs Against PLK1 J Natl Cancer Inst, June 2, 2004; 96(11): 862 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Spankuch-Schmitt, J. Bereiter-Hahn, M. Kaufmann, and K. Strebhardt Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells J Natl Cancer Inst, December 18, 2002; 94(24): 1863 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wu, I. Dmitriev, E. Kashentseva, T. Seki, M. Wang, and D. T. Curiel Construction and Characterization of Adenovirus Serotype 5 Packaged by Serotype 3 Hexon J. Virol., November 13, 2002; 76(24): 12775 - 12782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cuconati and E. White Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection Genes & Dev., October 1, 2002; 16(19): 2465 - 2478. [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Armstrong Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan Oncologist, October 1, 2002; 7(90005): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Herzog Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 3 - 10. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
